<?xml version="1.0" encoding="UTF-8"?>
<p>Currently, there are no effective antiviral drugs or vaccines that are available to treat EV-D68 infection. Treatment options are limited to supportive care for mild and severe cases. The Centers for Disease Control and Prevention (CDC) in the United States have tested 16 drugs as possible candidates for EV therapy. Among them, V-7074, being developed to combine with pocapavir to treat polio infection, and DAS 181, being developed for the treatment of influenza and parainfluenza infections, are thought to have the potential to inhibit EV-D68 viruses [
 <xref rid="B46-viruses-11-00490" ref-type="bibr">46</xref>]. Other potent compounds like rupintrivir, enviroxime, and others, are under pre-clinical evaluation [
 <xref rid="B47-viruses-11-00490" ref-type="bibr">47</xref>]. 
</p>
